SK12342000A3 - Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie - Google Patents
Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie Download PDFInfo
- Publication number
- SK12342000A3 SK12342000A3 SK1234-2000A SK12342000A SK12342000A3 SK 12342000 A3 SK12342000 A3 SK 12342000A3 SK 12342000 A SK12342000 A SK 12342000A SK 12342000 A3 SK12342000 A3 SK 12342000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- mono
- alkyl
- carbon atoms
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7636298P | 1998-02-27 | 1998-02-27 | |
PCT/IB1999/000206 WO1999043663A1 (en) | 1998-02-27 | 1999-02-05 | N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia |
Publications (1)
Publication Number | Publication Date |
---|---|
SK12342000A3 true SK12342000A3 (sk) | 2001-03-12 |
Family
ID=22131525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1234-2000A SK12342000A3 (sk) | 1998-02-27 | 1999-02-05 | Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie |
Country Status (39)
Country | Link |
---|---|
US (2) | US6492401B1 (es) |
EP (2) | EP1454902A1 (es) |
JP (2) | JP2002504546A (es) |
KR (4) | KR100449600B1 (es) |
CN (1) | CN1289326A (es) |
AP (1) | AP9901478A0 (es) |
AR (1) | AR015526A1 (es) |
AT (1) | ATE286034T1 (es) |
AU (1) | AU739403B2 (es) |
BG (1) | BG104803A (es) |
BR (1) | BR9908332A (es) |
CA (1) | CA2321642A1 (es) |
CO (1) | CO4980897A1 (es) |
DE (1) | DE69922930T2 (es) |
DK (1) | DK1056729T3 (es) |
DZ (1) | DZ2729A1 (es) |
EA (1) | EA003603B1 (es) |
ES (1) | ES2237080T3 (es) |
GT (1) | GT199900022A (es) |
HR (2) | HRP20000550A2 (es) |
HU (1) | HUP0204418A3 (es) |
ID (1) | ID25505A (es) |
IL (1) | IL136588A0 (es) |
IS (1) | IS5548A (es) |
NO (1) | NO20004192D0 (es) |
NZ (1) | NZ504769A (es) |
OA (1) | OA11450A (es) |
PA (1) | PA8468401A1 (es) |
PE (1) | PE20000334A1 (es) |
PL (1) | PL342444A1 (es) |
PT (1) | PT1056729E (es) |
SI (1) | SI1056729T1 (es) |
SK (1) | SK12342000A3 (es) |
TN (1) | TNSN99028A1 (es) |
TR (1) | TR200002480T2 (es) |
TW (1) | TWI226329B (es) |
WO (1) | WO1999043663A1 (es) |
YU (1) | YU46200A (es) |
ZA (1) | ZA991578B (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK12342000A3 (sk) * | 1998-02-27 | 2001-03-12 | Pfizer Products Inc. | Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie |
FR2795726A1 (fr) * | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
US6441176B1 (en) | 1999-10-29 | 2002-08-27 | Pfizer Inc. | Method for preparing sodium-hydrogen exchanger type 1 inhibitor |
UA72002C2 (en) * | 1999-10-29 | 2005-01-17 | Pfizer Prod Inc | Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
CA2398446A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
US6852733B2 (en) * | 2000-04-28 | 2005-02-08 | Pfizer Inc. | Sodium-hydrogen exchanger type 1 inhibitor |
CZ20023408A3 (cs) * | 2000-04-28 | 2004-01-14 | Pfizer Products Inc. | Inhibitor sodíko-vodíkových měničů typu 1 |
IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
JP2004514706A (ja) * | 2000-11-28 | 2004-05-20 | ファイザー・プロダクツ・インク | ナトリウム−水素交換体1型阻害剤の調製 |
US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
IL147696A0 (en) * | 2001-01-25 | 2002-08-14 | Pfizer Prod Inc | Combination therapy |
JP2004518686A (ja) * | 2001-01-31 | 2004-06-24 | ファイザー・プロダクツ・インク | ナトリウム−水素交換輸送体1型阻害剤のエタノラート |
WO2002098429A1 (en) * | 2001-06-07 | 2002-12-12 | Pfizer Products Inc. | Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat |
US7358267B2 (en) * | 2001-06-29 | 2008-04-15 | Amgen Inc. | Bis-aryl thiazole derivatives |
HUP0401853A2 (hu) * | 2001-11-02 | 2004-12-28 | Aventis Pharmaceuticals Inc. | Gyógyászati készítmény, ami egy adenozin A1/A2 agonistát és nátrium-hidrogén csere inhibitort tartalmaz |
MXPA04004685A (es) | 2001-12-19 | 2004-08-12 | Pfizer Prod Inc | Procedimientos para preparar inhibidores de tipo-1 de intercambiador sodio-hidrogeno. |
CA2472342A1 (en) * | 2002-01-30 | 2003-08-07 | Pfizer Products Inc. | Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide |
CA2483927A1 (en) * | 2002-05-02 | 2003-11-13 | Pfizer Products Inc. | Treatment of diabetes and diabetic complications with nhe-1 inhibitors |
US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
FR2840302B1 (fr) * | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
FR2842526B1 (fr) * | 2002-07-16 | 2007-07-13 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments |
FR2842524B1 (fr) | 2002-07-16 | 2005-04-22 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments |
FR2842525B1 (fr) | 2002-07-16 | 2005-05-13 | Aventis Pharma Sa | Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant |
US7365070B2 (en) * | 2002-12-04 | 2008-04-29 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
ZA200505734B (en) * | 2003-02-07 | 2006-12-27 | Daiichi Seiyaku Co | Pyrazole Derivative |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
PL1689757T3 (pl) | 2003-11-12 | 2015-05-29 | Sino Med Int Alliance Inc | Heterocykliczne związki kwasu boronowego |
TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
WO2005079803A1 (en) * | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
EP1778220A1 (en) | 2004-07-12 | 2007-05-02 | Phenomix Corporation | Constrained cyano compounds |
WO2006055463A2 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
WO2006055462A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
EP1853296B1 (fr) * | 2005-01-10 | 2012-06-20 | Debiopharm S.A. | Utilisation d'un undécapeptide cyclique pour la préparation d'un médicament administrable lors de situations ischémiques myocardiaques |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
EP2046753A2 (en) | 2006-07-06 | 2009-04-15 | Brystol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
JP2010524953A (ja) | 2007-04-17 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 縮合ヘテロ環11−β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤 |
JP2010534722A (ja) | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
CA2722772C (en) | 2008-04-28 | 2020-12-22 | Janssen Pharmaceutica N.V. | Benzoimidazoles as prolyl hydroxylase inhibitors |
US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
JP5621148B2 (ja) * | 2008-11-21 | 2014-11-05 | ラクオリア創薬株式会社 | 5−ht2b受容体拮抗活性を有する新規ピラゾール−3−カルボキサミド誘導体 |
WO2010094090A2 (en) * | 2009-02-18 | 2010-08-26 | Katholleke Universiteit Leuven | Synucleinopathies |
CN102971313A (zh) | 2010-04-14 | 2013-03-13 | 百时美施贵宝公司 | 新颖的葡糖激酶激活剂及其使用方法 |
CN102408385B (zh) * | 2011-06-20 | 2014-06-18 | 雅本化学股份有限公司 | 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法 |
CN102408386B (zh) * | 2011-07-27 | 2014-05-07 | 雅本化学股份有限公司 | 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法 |
CN103929964A (zh) | 2011-09-23 | 2014-07-16 | 拜耳知识产权有限责任公司 | 4-取代的1-苯基吡唑-3-甲酸衍生物作为对抗非生物植物胁迫的活性物质的用途 |
JP6122862B2 (ja) | 2011-10-25 | 2017-04-26 | ヤンセン ファーマシューティカ エヌ.ベー. | 1−(5,6−ジクロロ−1h−ベンゾ[d]イミダゾール−2−イル)−1h−ピラゾール−4−カルボン酸のメグルミン塩製剤 |
WO2013130411A1 (en) * | 2012-02-27 | 2013-09-06 | Essentialis, Inc. | Salts of potassium atp channel openers and uses thereof |
RU2733951C9 (ru) * | 2015-08-06 | 2020-12-22 | Убе Индастриз, Лтд. | Замещенные производные гуанидина |
WO2017057695A1 (ja) * | 2015-09-30 | 2017-04-06 | 東レ株式会社 | ジフェニルピラゾール誘導体及びその医薬用途 |
HUE054503T2 (hu) | 2015-12-16 | 2021-09-28 | Nippon Soda Co | Arilazol vegyület és kártevõ elleni szer |
US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2104931B1 (es) * | 1970-09-08 | 1975-01-10 | Ferlux | |
CA2121391A1 (en) * | 1993-04-28 | 1994-10-29 | Atsuyuki Kojima | Indoloylguanidine derivatives |
IL109570A0 (en) | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
EP0639573A1 (de) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
DE4412334A1 (de) | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
CA2160600A1 (en) * | 1994-10-18 | 1996-04-19 | Masahumi Kitano | Indoloylguanidine derivatives |
NZ314105A (en) | 1996-02-02 | 1997-12-19 | Sumitomo Pharma | Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring |
JPH09291076A (ja) | 1996-04-24 | 1997-11-11 | Sumitomo Pharmaceut Co Ltd | 置換グアニジン誘導体およびその製法 |
AR009435A1 (es) * | 1996-12-16 | 2000-04-12 | Yamanouchi Pharma Co Ltd | Derivado de guanaidina n-[carbonil(heteroaril-substituida de 5 miembros)], un inhibidor del intercambiador de na+/h+ que comprende dicho derivado y usosen la fabricacion de medicamentos. |
SK12342000A3 (sk) * | 1998-02-27 | 2001-03-12 | Pfizer Products Inc. | Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie |
-
1999
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/sk unknown
- 1999-02-05 ID IDW20001633A patent/ID25505A/id unknown
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/ko not_active IP Right Cessation
- 1999-02-05 SI SI9930743T patent/SI1056729T1/xx unknown
- 1999-02-05 AT AT99901083T patent/ATE286034T1/de not_active IP Right Cessation
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/ko not_active Application Discontinuation
- 1999-02-05 EP EP04008203A patent/EP1454902A1/en not_active Withdrawn
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-05 DK DK99901083T patent/DK1056729T3/da active
- 1999-02-05 IL IL13658899A patent/IL136588A0/xx unknown
- 1999-02-05 DE DE69922930T patent/DE69922930T2/de not_active Expired - Fee Related
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 CN CN99802628A patent/CN1289326A/zh active Pending
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/pt not_active IP Right Cessation
- 1999-02-05 CA CA002321642A patent/CA2321642A1/en not_active Abandoned
- 1999-02-05 ES ES99901083T patent/ES2237080T3/es not_active Expired - Lifetime
- 1999-02-05 EA EA200000789A patent/EA003603B1/ru not_active IP Right Cessation
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/xx unknown
- 1999-02-05 YU YU46200A patent/YU46200A/sh unknown
- 1999-02-05 PT PT99901083T patent/PT1056729E/pt unknown
- 1999-02-05 EP EP99901083A patent/EP1056729B1/en not_active Expired - Lifetime
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/ko not_active Application Discontinuation
- 1999-02-05 PL PL99342444A patent/PL342444A1/xx not_active Application Discontinuation
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/hu not_active Application Discontinuation
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/en not_active Application Discontinuation
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/ko not_active IP Right Cessation
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/ja active Pending
- 1999-02-22 GT GT199900022A patent/GT199900022A/es unknown
- 1999-02-22 TW TW088102574A patent/TWI226329B/zh active
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/es not_active Application Discontinuation
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/xx active
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/fr unknown
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/es unknown
- 1999-02-25 AR ARP990100791A patent/AR015526A1/es unknown
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/xx unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/es unknown
-
2000
- 2000-06-27 IS IS5548A patent/IS5548A/is unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192D0/no not_active Application Discontinuation
- 2000-08-24 HR HR20000550A patent/HRP20000550A2/hr not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/bg unknown
-
2001
- 2001-08-29 HR HR20010666A patent/HRP20010666A2/hr not_active Application Discontinuation
-
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
-
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK12342000A3 (sk) | Deriváty n-[(substituovaný päťčlenný di-alebo triáza-di- -nenasýtený kruh)karbonyl] guanidínu pre liečenie ischémie | |
US6403620B1 (en) | Inhibitors of factor Xa with a neutral P1 specificity group | |
KR100569324B1 (ko) | Hiv 치료용 피라졸 유도체 | |
JP4319255B2 (ja) | Xa因子阻害剤としての新規グアニジン模倣化合物類 | |
CA2577420C (en) | Lonidamine analogues and their use in male contraception and cancer treatment | |
KR20020034206A (ko) | 허혈증 치료용 화합물 | |
WO2005090328A1 (ja) | 複素環化合物およびその用途 | |
CZ20032321A3 (en) | Fused heterocyclic compounds | |
JPH11302277A (ja) | ピラゾール誘導体、その製法および医薬としてのその使用 | |
CA2494321C (en) | 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | |
MXPA02010600A (es) | Inhibidor del intercambiador de sodio-hidrogeno de tipo 1. | |
CZ20002988A3 (cs) | Deriváty N-{(substituovaný pětičlenný di- nebo triaza-di-nenasycený kruh)karbonyl} guanidinu pro léčení ischemie | |
KR20030056481A (ko) | 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체 | |
MXPA00008400A (es) | Derivados de guanidina n-[carbonil(anillo diinsaturado triaza o ditriaza de cinco miembros sustituido)]para el tratamiento de isquemia | |
AU779106B2 (en) | Method for preparing sodium-hydrogen exchanger type 1 inhibitor | |
ES2305563T3 (es) | Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el vih. | |
EP1224179A2 (en) | Sodium-hydrogen exchanger type 1 inhibitor crystals | |
CN114846004A (zh) | 新型抗疟药 | |
LT4702B (lt) | Xa faktoriaus inhibitorius su neutralia p1 specifine grupe | |
LT4673B (lt) | Azoto heteroaromatiniai junginiai kaip faktoriaus xa inhibitoriai |